Anthem Equity News

FDA Approves the SynCardia Total Artificial Heart for Destination Therapy Study »

19 patients who are not eligible for a donor heart transplant will participate in the pivotal clinical study to evaluate the SynCardia Total Artificial Heart for permanent use. TUCSON, Ariz. – Jan 6, 2015 – SynCardia Systems, Inc. has received FDA approval to conduct a clinical study of the effectiveness of the SynCardia temporary Total […]

SynCardia-Shepherd FDA Approves the Freedom® Portable Driver That Powers The SynCardia Total Artificial Heart »

“These patients can be discharged and live in their homes and communities while they wait for their matching donor hearts.”

7-14-2014 10-28-38 AM Man Saved by First Total Artificial Heart Implant at Carolinas Medical Center »

Doctors at Carolinas Medical Center were the first to implant the total artificial heart or TAH, in the Carolinas.

Heart only from logo First Patient Receives HeartAssist5® VAD Following CE Mark Approval »

The first advanced stage heart failure patient received its next generation HeartAssist5® Ventricular Assist Device (VAD) since the company earned CE Mark approval for design enhancements just weeks ago.

blue man ReliantHeart’s HeartAssist5® achieves European CE Mark, which includes True Flow Remote Monitoring »

ReliantHeart’s HeartAssist5® achieves European CE Mark, which includes True Flow Remote Monitoring. Remote Monitoring via vadlink.com of True Flow, Speed and Power is only available on one VAD: the HeartAssist5®.

pump ReliantHeart goes head-to-head with Thoratec to aim for U.S. LVAD market »

ReliantHeart touts study data finding that its HeartAssist5 left ventricular assist device poses a lower risk of blood clots and damage compared with Thoratec’s HeartMate II.

HA5-cut-away Thrombus Formation Patterns Absent in HeartAssist5 »

Head to Head thrombogenic performance comparative study of the two VADs: Thoratec HeartMate II and the ReliantHeart – HeartAssist 5, demonstrates that Clotting and Thrombus formation patterns observed in the HeartMate II are absent in the HeartAssist5.

Heart only from logo SynCardia’s Ford tackles turnaround of heart-pump maker ReliantHeart »

In late October, Ford launched a new company, ReliantHeart Inc., formed from the bankruptcy assets of Houston-based MicroMed Technology Inc. The company’s HeartAssist 5 is the only VAD that offers constant monitoring of blood flow and heart function, Ford said. The roughly $100,000 device uses an ultrasonic probe to collect flow and other data and relay it to a wireless controller that can be accessed by health-care providers and patients.

HA5-white-med-150x150 ReliantHeart HeartAssist5® VAD achieves CE Mark for European distribution »

The ReliantHeart HeartAssist 5®Ventricular Assist Device (VAD) has been CE Mark approved in Europe for use in patients requiring ventricular support due to end stage heart failure. The CE Mark for the HeartAssist 5® was previously granted to MicroMed Technology, Inc. and was first available for European distribution in 2009.

blue man ReliantHeart to manufacture, sell and support the HeartAssist5® VAD with Rodger Ford as CEO »

ReliantHeart, Inc. has become the successor-in-interest to the assets of MicroMed Technology, Inc., the manufacturer of a class III ventricular assist device (VAD) called the HeartAssist5®. Rodger Ford will serve as Director and Chief Executive Officer of ReliantHeart. Mr. Ford was previously the CEO of Tucson-based artificial heart company SynCardia.